2022 World Conference on Lung Cancer (ePosters)-EP08.01-026. Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients

EP08.01-026. Influence of Brain Metastases on Survival of KRASG12C Mutated Stage IV Immune Checkpoint Inhibitor Treated Non-Small Cell Lung Cancer Patients

Back to course

Pdf Summary

This study aimed to investigate the incidence and outcomes of patients with KRAS G12C mutated non-small cell lung cancer (NSCLC) who had brain metastases (BM) at the time of diagnosis and received first-line immune checkpoint inhibitor (ICI) treatment. The data was collected retrospectively from the Netherlands Cancer Registry.<br /><br />Out of the patients included in the study, 35.3% underwent brain imaging, and more than half of them had brain metastases. The patients with BM were younger and had a higher number of organs affected by metastasis compared to those without BM.<br /><br />The results showed that the 1-year cumulative incidence of intracranial progression was higher in patients with BM compared to those without BM. However, there was no significant difference in median progression-free survival (PFS) or overall survival (OS) between the two groups.<br /><br />These findings suggest that regular brain imaging during (chemo)-ICI treatment is necessary due to the higher frequency of intracranial progression in patients with BM. However, the presence of BM at diagnosis did not appear to have a significant impact on the survival of patients with KRAS G12C mutated NSCLC treated with first-line (chemo)-ICI.<br /><br />In conclusion, this study highlights the frequency of brain metastases in KRAS G12C mutated NSCLC patients and the need for monitoring during treatment. It also suggests that the presence of BM at diagnosis does not affect survival outcomes in patients treated with first-line (chemo)-ICI. Further research is needed to validate these findings and explore potential treatment strategies for patients with BM.

Asset Subtitle

Esther M Swart

Meta Tag

Speaker Esther M Swart

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

KRAS G12C mutated non-small cell lung cancer

brain metastases

immune checkpoint inhibitor treatment

Netherlands Cancer Registry

incidence

outcomes

brain imaging

metastasis

intracranial progression

progression-free survival